JP2022507505A5 - - Google Patents

Info

Publication number
JP2022507505A5
JP2022507505A5 JP2021526491A JP2021526491A JP2022507505A5 JP 2022507505 A5 JP2022507505 A5 JP 2022507505A5 JP 2021526491 A JP2021526491 A JP 2021526491A JP 2021526491 A JP2021526491 A JP 2021526491A JP 2022507505 A5 JP2022507505 A5 JP 2022507505A5
Authority
JP
Japan
Prior art keywords
alkyl
membered
aryl
substituted
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021526491A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022507505A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/061531 external-priority patent/WO2020102574A1/en
Publication of JP2022507505A publication Critical patent/JP2022507505A/ja
Publication of JP2022507505A5 publication Critical patent/JP2022507505A5/ja
Pending legal-status Critical Current

Links

JP2021526491A 2018-11-16 2019-11-14 Nlrp活性に関連する状態を治療するための化合物及び組成物 Pending JP2022507505A (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201862768805P 2018-11-16 2018-11-16
US62/768,805 2018-11-16
US201862769151P 2018-11-19 2018-11-19
US201862769165P 2018-11-19 2018-11-19
US62/769,165 2018-11-19
US62/769,151 2018-11-19
US201962795981P 2019-01-23 2019-01-23
US62/795,981 2019-01-23
US201962796361P 2019-01-24 2019-01-24
US201962796356P 2019-01-24 2019-01-24
US62/796,356 2019-01-24
US62/796,361 2019-01-24
US201962898241P 2019-09-10 2019-09-10
US62/898,241 2019-09-10
PCT/US2019/061531 WO2020102574A1 (en) 2018-11-16 2019-11-14 The compounds and compositions for treating conditions associated with nlrp activity

Publications (2)

Publication Number Publication Date
JP2022507505A JP2022507505A (ja) 2022-01-18
JP2022507505A5 true JP2022507505A5 (cg-RX-API-DMAC7.html) 2022-11-01

Family

ID=70731718

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021526491A Pending JP2022507505A (ja) 2018-11-16 2019-11-14 Nlrp活性に関連する状態を治療するための化合物及び組成物

Country Status (5)

Country Link
US (1) US20230059136A1 (cg-RX-API-DMAC7.html)
EP (1) EP3880658A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022507505A (cg-RX-API-DMAC7.html)
CN (1) CN113227055A (cg-RX-API-DMAC7.html)
WO (1) WO2020102574A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000027251A1 (it) * 2020-11-13 2022-05-13 Donatella Boschi Inibitori della diidroorotato deidrogenasi umana (hdhodh) per l'uso come antivirali
CN117279903A (zh) * 2021-02-10 2023-12-22 杭州英创医药科技有限公司 作为nlrp3抑制剂的化合物
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
EP4791725A1 (en) 2023-10-11 2026-08-19 Syngenta Crop Protection AG Microbiocidal pyridyl pyrazole derivatives
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2085297A1 (en) * 1991-12-20 1993-06-21 James Edward Ray Sulfonimidamides
JP6929792B2 (ja) * 2015-02-16 2021-09-01 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用
MA44729A (fr) * 2016-04-18 2021-05-12 Novartis Ag Composés et compositions pour traiter des états associés à une activité de nlrp
US11447460B2 (en) * 2016-04-18 2022-09-20 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
EP3445761A1 (en) * 2016-04-19 2019-02-27 Innate Tumor Immunity, Inc. Nlrp3 modulators
US11370763B2 (en) * 2017-07-24 2022-06-28 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity

Similar Documents

Publication Publication Date Title
JP2022507065A5 (cg-RX-API-DMAC7.html)
JP2022505525A5 (cg-RX-API-DMAC7.html)
JP2022507506A5 (cg-RX-API-DMAC7.html)
JP2020528889A5 (cg-RX-API-DMAC7.html)
JP2019519598A5 (cg-RX-API-DMAC7.html)
ES2927777T3 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP
CA2899706C (en) Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
ES2640063T3 (es) Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis B
JP2022506898A5 (cg-RX-API-DMAC7.html)
HRP20251344T1 (hr) SPOJEVI I PRIPRAVCI ZA LIJEČENJE STANJA POVEZANIH S AKTIVNOŠĆU NLRP-a
JP2019518071A5 (cg-RX-API-DMAC7.html)
JP2020537657A5 (cg-RX-API-DMAC7.html)
JP2021534124A5 (cg-RX-API-DMAC7.html)
JP2024512154A5 (cg-RX-API-DMAC7.html)
JP2022513959A (ja) 大環状化合物及び疾患の処置におけるそれらの使用
JP2019515952A5 (cg-RX-API-DMAC7.html)
WO2020163823A2 (en) Therapeutic agents and methods of treatment
CN105001165A (zh) 取代的二氨基嘧啶其组合物,和用其治疗的方法
AU2015272398B2 (en) Polyene macrolide derivative
WO2024088408A1 (zh) 一种含氮杂环化合物、其药学上可接受的盐及其制备方法与应用
AU2017253937A1 (en) Compounds and compositions for treating conditions associated with NLRP activity
JP7858508B2 (ja) 近視の治療、近視の予防および/または近視の進行抑制のための医薬
TW201617331A (zh) 異吲哚啉衍生物
CN105051046A (zh) β-氨基羰基类化合物、其制备方法、药物组合物及其用途
JP2021524856A5 (cg-RX-API-DMAC7.html)